Supplements and Featured Publications
Abriendo Puertas a los Profesionales con el Multimodal Maestro2
The Only Branded Steroid Indicated for Inflammation Associated with a Range of Ocular Surface Conditions
A Reliable Treatment for Blepharitis/Meibomian Gland Dysfunction, with Increased Ocular Bioavailability
Glaucoma 360: Highlights from 2021
Glaucoma 360: Highlights from 2020
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: Peter Kaiser explains the ongoing SOL-1 and SOL-R study of OTX-TKI
2
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa
3
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA
4
Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial
5
.png "Optometry Times"){kind=logo}
